Tocilizumab in systemic lupus erythematosus: Data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study-Reference-Cited by-同舟云学术

Tocilizumab in systemic lupus erythematosus: Data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study

Published:2010-02 Issue:2 Volume:62 Page:542-552
ISSN:0004-3591
Container-title:Arthritis & Rheumatism
language:en
Short-container-title:Arthritis Rheum

Author:

Illei Gabor G.,Shirota Yuko,Yarboro Cheryl H.,Daruwalla Jimmy,Tackey Edward,Takada Kazuki,Fleisher Thomas,Balow James E.,Lipsky Peter E.

Publisher

Wiley

Subject

Pharmacology (medical),Immunology,Rheumatology,Immunology and Allergy

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/art.27221/fullpdf

Reference28 articles.

1. IL-6: from laboratory to bedside;Kishimoto;Clin Rev Allergy Immunol,2005

2. Abnormal distribution of IL-6 receptor in aged MRL/lpr mice: elevated expression on B cells and absence on CD4+ cells;Kobayashi;Int Immunol,1992

3. Serum soluble interleukin-6 receptor in MRL/lpr mice is elevated with age and mediates the interleukin-6 signal;Suzuki;Eur J Immunol,1993

4. Age-associated increase in interleukin 6 in MRL/lpr mice;Tang;Int Immunol,1991

5. Interleukin-6 exacerbates glomerulonephritis in (NZB × NZW)F1 mice;Ryffel;Am J Pathol,1994

Cited by 446 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeted therapies in SLE;Dubois' Lupus Erythematosus and Related Syndromes;2025

2. Cytokines in lupus;Dubois' Lupus Erythematosus and Related Syndromes;2025

3. The musculoskeletal system and bone metabolism;Dubois' Lupus Erythematosus and Related Syndromes;2025

4. Pathogenic role of anti‐nuclear autoantibodies in systemic sclerosis: Insights from other rheumatic diseases;Immunological Reviews;2024-09-09

5. Efficacy and Safety of Upadacitinib or Elsubrutinib Alone or in Combination for Patients With Systemic Lupus Erythematosus: A Phase 2 Randomized Controlled Trial;Arthritis & Rheumatology;2024-08-07